FUKOKU MUTUAL LIFE INSURANCE Co Has $19.72 Million Stake in Johnson & Johnson $JNJ

FUKOKU MUTUAL LIFE INSURANCE Co reduced its stake in Johnson & Johnson (NYSE:JNJ) by 0.5% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 129,118 shares of the company’s stock after selling 615 shares during the quarter. FUKOKU MUTUAL LIFE INSURANCE Co’s holdings in Johnson & Johnson were worth $19,723,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Brighton Jones LLC grew its position in shares of Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after purchasing an additional 6,332 shares during the last quarter. Wealth Group Ltd. acquired a new stake in Johnson & Johnson in the 1st quarter valued at approximately $218,000. Smart Money Group LLC increased its position in Johnson & Johnson by 6.5% in the 1st quarter. Smart Money Group LLC now owns 6,687 shares of the company’s stock worth $1,109,000 after buying an additional 407 shares during the period. GW&K Investment Management LLC lifted its holdings in shares of Johnson & Johnson by 4.7% during the first quarter. GW&K Investment Management LLC now owns 3,075 shares of the company’s stock worth $510,000 after buying an additional 137 shares during the last quarter. Finally, United Bank lifted its holdings in shares of Johnson & Johnson by 110.7% during the first quarter. United Bank now owns 9,279 shares of the company’s stock worth $1,539,000 after buying an additional 4,876 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $203.04 on Thursday. The firm has a market cap of $489.18 billion, a P/E ratio of 19.60, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38. The firm’s 50-day simple moving average is $187.24 and its 200-day simple moving average is $170.99. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $203.48. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The firm had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. As a group, research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.6%. Johnson & Johnson’s payout ratio is currently 50.19%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.16% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on JNJ shares. Wells Fargo & Company set a $212.00 target price on shares of Johnson & Johnson and gave the stock an “overweight” rating in a research report on Friday, October 3rd. Weiss Ratings restated a “buy (b)” rating on shares of Johnson & Johnson in a research report on Friday, October 31st. Erste Group Bank raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Wednesday, July 23rd. Loop Capital set a $190.00 target price on Johnson & Johnson in a research report on Wednesday, October 22nd. Finally, Stifel Nicolaus upped their price target on Johnson & Johnson from $165.00 to $190.00 and gave the company a “hold” rating in a report on Wednesday, October 15th. Four analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $201.05.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.